Acorda Therapeutics Inc (NASDAQ:ACOR) Sentiment Worsened, Because

May 16, 2018 - By Rodney Autry

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Logo

Sentiment for Acorda Therapeutics Inc (NASDAQ:ACOR)

Acorda Therapeutics Inc (NASDAQ:ACOR) institutional sentiment decreased to 0.99 in 2017 Q4. Its down -0.23, from 1.22 in 2017Q3. The ratio dropped, as 69 active investment managers increased and started new positions, while 70 decreased and sold their equity positions in Acorda Therapeutics Inc. The active investment managers in our partner’s database now have: 48.17 million shares, down from 51.31 million shares in 2017Q3. Also, the number of active investment managers holding Acorda Therapeutics Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 24 Reduced: 46 Increased: 46 New Position: 23.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company has market cap of $1.15 billion. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It currently has negative earnings. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

The stock decreased 0.20% or $0.05 during the last trading session, reaching $24.45. About 286,709 shares traded. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has declined 10.61% since May 16, 2017 and is downtrending. It has underperformed by 22.16% the S&P500.

Analysts await Acorda Therapeutics, Inc. (NASDAQ:ACOR) to report earnings on July, 26. They expect $0.37 earnings per share, up 305.56 % or $0.55 from last year’s $-0.18 per share. ACOR’s profit will be $17.42 million for 16.52 P/E if the $0.37 EPS becomes a reality. After $-0.18 actual earnings per share reported by Acorda Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -305.56 % EPS growth.

Partner Fund Management L.P. holds 1.76% of its portfolio in Acorda Therapeutics, Inc. for 3.45 million shares. Partner Investment Management L.P. owns 53,442 shares or 1.32% of their US portfolio. Moreover, Malaga Cove Capital Llc has 0.57% invested in the company for 47,313 shares. The New York-based Pura Vida Investments Llc has invested 0.56% in the stock. Spark Investment Management Llc, a New York-based fund reported 409,100 shares.

Since January 1, 0001, it had 0 insider purchases, and 3 insider sales for $2.04 million activity.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Coverage

Ratings analysis reveals 33% of Acorda Therapeutics’s analysts are positive. Out of 6 Wall Street analysts rating Acorda Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $1700 while the high is $34.0. The stock’s average target of $22.75 is -6.95% below today’s ($24.45) share price. ACOR was included in 12 notes of analysts from November 20, 2017. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Buy” rating given on Monday, November 20 by H.C. Wainwright. The stock has “Hold” rating by Cantor Fitzgerald on Wednesday, May 2. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Buy” rating given on Wednesday, January 17 by H.C. Wainwright. The company was upgraded on Wednesday, February 7 by Goldman Sachs. Cantor Fitzgerald maintained the stock with “Hold” rating in Thursday, March 29 report. The company was upgraded on Thursday, February 15 by Piper Jaffray. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) earned “Hold” rating by Piper Jaffray on Tuesday, November 28. The firm has “Hold” rating given on Wednesday, January 31 by Janney Capital. The rating was maintained by H.C. Wainwright with “Buy” on Monday, April 2. The rating was maintained by H.C. Wainwright on Thursday, May 3 with “Buy”.

More important recent Acorda Therapeutics, Inc. (NASDAQ:ACOR) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings” on May 02, 2018, also Globenewswire.com published article titled: “Detailed Research: Economic Perspectives on First American, Greenhill & Co., Acorda Therapeutics, Deckers Outdoor …”, Streetinsider.com published: “Acorda Therapeutics (ACOR) Misses Q1 EPS by 33c, Revenues Miss” on May 02, 2018. More interesting news about Acorda Therapeutics, Inc. (NASDAQ:ACOR) was released by: Benzinga.com and their article: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” with publication date: April 29, 2018.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.